Japan Chemical Research Looks To Grow Market Shares For Growth Hormone Products
This article was originally published in PharmAsia News
Executive SummaryJapan Chemical Research 2008 sales increased by 1.8 percent to ¥12.82 billion, through growth of the company's major product, human growth hormone Growject (somatropin). For fiscal year 2009, the company estimates a 1.8 percent increase in sales and 8 percent increase in income. JCR submitted a new drug application in Japan for recombinant erythropoietin to treat nephrogenic anemia last November, aiming for a market launch in 2010. JCR also begins clinical trials for its mesenchymal stem cell therapeutic agent in Japan. (Click here for more - Japanese language
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.